On 5 February 2019, the European Hematology Association (EHA) and the HARMONY Alliance organized the 2nd EHA-HARMONY KOL meeting. The objective of this meeting was to discuss the results of current projects, talk about the newly proposed projects and align on the outcome definition initiative of WP2. Invited to this meeting were the HARMONY Key Opinion Leaders of the 7 Hematological Malignancies Disease Groups. Also invited were representatives from the HARMONY Patient Cluster and from the HARMONY EFPIA (the European Federation of Pharmaceutical Industries and Associations) Partners.
HARMONY focuses on Acute Lymphoblastic leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Multiple Myeloma, and Pediatric Hematologic Malignancies. Read more about each of the 7 diseases >.
The HARMONY KOLs are partners of the HARMONY Alliance. We currently have 53 Partners, including 8 pharmaceutical companies from EFPIA, and 27 Associated Members. This large number of stakeholders across different European countries has traditionally made a fragmented playing field, from basic hematology research all the way to approval processes for new medicines. HARMONY was created to fill a specific need in blood cancer treatments and functions as the interface between all stakeholders. Never has a European public-private initiative had such ambitious goals for international collaboration in big data and HMs. Read more >
Receive the latest news. Click here to subscribe!